Under construction – not a live service
Sign in
Taking people in JapanNo phase

Revolade Tablets Specified Drug-use Survey

Key facts

Where
Amagasaki, Chiba, Chuo Ku, Izumi, Kobe, Matsumoto, Nagoya, Ohtsu, Osaka, Ōta-ku, Saitama, Sakai, Setagaya-ku, Shimajiri-Gun, Toyoake, and Wakayama, JapanSee the 16 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 17 years old?

Source: NCT06287268, who can take part

Where in Japan

  • Amagasaki, HyōgoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • ChibaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Chuo Ku, TokyoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Izumi, OsakaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Kobe, HyōgoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Matsumoto, NaganoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Nagoya, Aichi-kenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Ohtsu, ShigaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • OsakaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Ōta-ku, TokyoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • SaitamaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Sakai, OsakaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Setagaya-ku, TokyoHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Shimajiri-Gun, OkinawaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • Toyoake, Aichi-kenHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
  • WakayamaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Novartis Pharmaceuticals
Trial code
NCT06287268
Record updated
19 February 2026
Original description
This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).Read full original descriptionShow less

Revolade Tablets Specified Drug-use Survey (Pediatric Aplastic Anemia Naive to Treatment With Anti-thymocyte Immunoglobulin, CETB115G1401)

This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).

Inclusion: Patients whose legally acceptable representative has given written consent for cooperation in this survey prior to enrollment in this survey; Patients aged ≥ 6 years and < 18 years at the start of treatment with eltrombopag; Pediatric patients with AA who receive eltrombopag for the first time in combination with ATG after the approval of additional dosage and administration for "ATG-naïve pediatric patients with AA".

Exclusion: Patients who have received ATG without concomitant use of eltrombopag; Patients with suspected or confirmed diagnosis of myelodysplastic syndrome (MDS) at the start of treatment with eltrombopag; Patients who have received any drug products containing the same ingredient as eltrombopag (including investigational products); Patients with congenital AA.

ClinicalTrials.gov NCT06287268